Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：232
|
作者：
Verheijen, Remy B. [1 ]
Yu, Huixin [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [1 ,3 ]
Steeghs, Neeltje [2 ]
Huitema, Alwin D. R. [1 ,4 ]
机构：
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands
[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands
[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期
关键词：
CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;
D O I：
10.1002/cpt.787
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
引用
收藏
页码：765 / 776
页数：12
相关论文
共 50 条
  • [1] Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
    van der Kleij, Maud B. A.
    Guchelaar, Niels A. D.
    Mathijssen, Ron H. J.
    Versluis, Jurjen
    Huitema, Alwin D. R.
    Koolen, Stijn L. W.
    Steeghs, Neeltje
    CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1333 - 1364
  • [2] Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
    Yu, Huixin
    Steeghs, Neeltje
    Nijenhuis, Cynthia M.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 305 - 325
  • [3] Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology
    Janssen, Julie M.
    Dorlo, Thomas P. C.
    Steeghs, Neeltje
    Beijnen, Jos H.
    Hanff, Lidwien M.
    van Eijkelenburg, Natasha K. A.
    van der Lugt, Jasper
    Zwaan, C. Michel
    Huitema, Alwin D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 494 - 505
  • [4] Therapeutic drug monitoring and tyrosine kinase inhibitors
    Herviou, Pauline
    Thivat, Emilie
    Richard, Damien
    Roche, Lucie
    Dohou, Joyce
    Pouget, Melanie
    Eschalier, Alain
    Durando, Xavier
    Authier, Nicolas
    ONCOLOGY LETTERS, 2016, 12 (02) : 1223 - 1232
  • [5] Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors
    Bouchet, Stephane
    Molimard, Mathieu
    THERAPIE, 2022, 77 (02): : 157 - 170
  • [6] Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study
    Escudero-Ortiz, Vanesa
    Dominguez-Lenero, Vanessa
    Catalan-Latorre, Ana
    Rebollo-Liceaga, Joseba
    Sureda, Manuel
    PHARMACEUTICS, 2022, 14 (06)
  • [7] Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
    Henriksen, Jakob N.
    Andersen, Charlotte U.
    Fristrup, Niels
    CLINICAL GENITOURINARY CANCER, 2024, 22 (03)
  • [8] Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study
    Groenland, Stefanie L.
    van Eerden, Ruben A. G.
    Verheijen, Remy B.
    Koolen, Stijn L. W.
    Moes, Dirk Jan A. R.
    Desar, Ingrid M. E.
    Reyners, Anna K. L.
    Gelderblom, Hans J.
    van Erp, Nielka P.
    Mathijssen, Ron H. J.
    Huitema, Alwin D. R.
    Steeghs, Neeltje
    THERAPEUTIC DRUG MONITORING, 2019, 41 (05) : 561 - 567
  • [9] Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Implications for Therapeutic Drug Monitoring
    Josephs, Debra H.
    Fisher, Danielle S.
    Spicer, James
    Flanagan, Robert J.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 562 - 587
  • [10] Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives
    Falkowski, Sabrina
    Woillard, Jean-Baptiste
    THERAPEUTIC DRUG MONITORING, 2019, 41 (05) : 568 - 574
12345